NurExone Biologic (FRA:J90) Total Payout Ratio: 0.50 (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J90 NurExone Biologic Inc FRA:J90
34 GF Score
Price €0.33
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Total Payout Ratio?

NurExone Biologic FRA:J90 34 Total Payout Ratio is 0.50 as of Aug. 30, 2026. GuruFocus rates FRA:J90 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

NurExone Biologic's current Total Payout Ratio is 0.50.

NurExone Biologic Total Payout Ratio Related Terms

NurExone Biologic Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Total Payout Ratio Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
1.35 0.29 0.29 0.54 0.46

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.86 0.68 0.00 0.36

FRA:J90 vs VRTX, REGN, RVMD: Total Payout Ratio Comparison

For the Biotechnology subindustry, NurExone Biologic's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Total Payout Ratio falls into.


FRA:J90
34GF Score
NurExone Biologic Inc FRA:J90
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

NurExone Biologic's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 2.481 + 0) / -5.452
=0.46

NurExone Biologic's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.548 + 0) / -1.528
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.50 mean?
NurExone Biologic (FRA:J90) has a Total Payout Ratio of 0.50 as of Aug. 30, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on NurExone Biologic and its competitors.
Is NurExone Biologic's Total Payout Ratio too high?
NurExone Biologic's current Total Payout Ratio is 0.50. Overall, NurExone Biologic has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Total Payout Ratio compare to VRTX and REGN?
NurExone Biologic's Total Payout Ratio of 0.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current Total Payout Ratio is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Total Payout Ratio of 0.50. The current Total Payout Ratio is 0.50. NurExone Biologic's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Total Payout Ratio is 0.50 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
34GF Score

Get the complete analysis for FRA:J90

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price